Implications of growth factor alterations in the treatment of pancreatic cancer

被引：7

作者：

Márk Juhász

Barbara Nitsche

Peter Malfertheiner

Matthias PA Ebert

机构：

[1] Dept. Gastroenterology Hepatology, Otto-von-Guericke University, D-39120 Magdeburg

[2] Department of Medicine, Semmelweis University, Budapest 1088

来源：

Molecular Cancer | / 2卷 / 1期

关键词：

Growth factor; Pancreatic cancer; Treatment; Tyrosine kinase inhibitors;

D O I：

10.1186/1476-4598-2-5

中图分类号：

学科分类号：

摘要：

Pancreatic cancer ranks fifth as a cause of cancer-related death in the world with an overall 5-year survival rate of less than 1% and a median survival of less than a year after tumour detection. Most of these patients have already metastases at the time of diagnosis. The oncologic strategies such as chemotherapy, radiotherapy, antihormonal modalities or the systemic use of specific monoclonal antibodies have not achieved a significant improvement in the survival of pancreatic cancer patients. Recent studies suggest that alterations in molecular pathways, particularly in growth factor mediated mechanisms, that regulate cell proliferation and differentiation play a pivotal role in the pathogenesis of this cancer. The molecular knowledge regarding changes in the expression of growth factors in pancreatic cancer has the potential to improve diagnostic and therapeutic treatment strategies in the near future. © 2003 Jushász et al; licensee BioMed Central Ltd.

引用

页数：7

共 60 条

[1]

Urrutia R., DiMagno E.P., Pancreatic cancer: Cellular and molecular mechanisms, Encyclopedia of Cancer, pp. 1201-1211, (1996)

[2]

Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M., Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes, Cell, 53, pp. 549-554, (1988)

[3]

Grunewald K., Lyons J., Frohlich A., Feichtinger H., Weger R.A., Schwab G., Janssen J.W., Bartram C.R., High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas, Int. J. Cancer, 43, pp. 1037-1041, (1989)

[4]

Ebert M.P., Hoffmann J., Schneider-Stock R., Kasper H.U., Schulz H.U., Lippert H., Roessner A., Malfertheiner P., Analysis of K-ras gene mutations in rare pancreatic and ampullary tumours, Eur. J. Gastroenterol. Hepatol., 10, pp. 1025-1029, (1998)

[5]

Luttges J., Schlehe B., Menke M.A., Vogel I., Henne-Bruns D., Kloppel G., The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium, Cancer, 85, pp. 1703-1717, (1999)

[6]

Bramhall S.R., The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis, Int. J. Pancreatol., 23, pp. 83-100, (1998)

[7]

Barton C.M., Staddon S.L., Hughes C.M., Hall P.A., O'Sullivan C., Kloppel G., Theis B., Russell R.C., Neoptolemos J., Williamson R.C., Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer, Br. J. Cancer, 64, pp. 1076-1082, (1991)

[8]

Kalthoff H., Schmiegel W., Roeder C., Kasche D., Schmidt A., Lauer G., Thiele H.G., Honold G., Pantel K., Riethmuller G., p53 and K-RAS alterations in pancreatic epithelial cell lesions, Oncogene, 8, pp. 289-298, (1993)

[9]

Casey G., Yamanaka Y., Friess H., Kobrin M.S., Lopez M.E., Buchler M., Beger H.G., Korc M., p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis, Cancer Lett., 69, pp. 151-160, (1993)

[10]

Ebert M., Yokoyama M., Kobrin M.S., Friess H., Buchler M.W., Korc M., Increased MDM2 expression and immunoreactivity in human pancreatic ductal adenocarcinoma, Int. J. Oncol., 5, pp. 1279-1284, (1994)

← 1 2 3 4 5 6 →